A case of carbidopa/levodopa associated colitis mimicking inflammatory bowel disease
Carbidopa/levodopa is widely used in the management of Parkinson’s disease. We report a 77-year-old male with Parkinson’s disease who developed severe, protracted pancolitis and ileitis after 5-months of treatment with carbidopa/levodopa. The clinical presentation and endoscopic findings initially r...
Main Authors: | Michael J. Steel, James Conner, Sandra Nelles, Richard Kirsch |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-06-01
|
Series: | Human Pathology Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772736X22000603 |
Similar Items
-
Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide
by: Noriyuki Miyaue, et al.
Published: (2022-07-01) -
Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
by: Mezin Öthman, et al.
Published: (2021-03-01) -
Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease
by: Michael J. Soileau, et al.
Published: (2023-01-01) -
The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
by: Pedersen SW, et al.
Published: (2017-01-01) -
Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
by: Peter LeWitt, et al.
Published: (2023-01-01)